NCT06500507View on ClinicalTrials.gov

A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

January 31, 2027

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG

QLS4131 Injection

Participants confirming to the eligibility criteria will be assigned to 1 of the 9 dose groups (0.06/0.3/1 \~ 600 ug/kg, respectively) based on the sequence of inclusion.

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06500507 - A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter